Introducing ReciPredict: Revolutionising Drug Product Development and Manufacturing

September 04 2024

• 30-70% API consumption reduction during development and scale up
• Reduce time to clinical stage by up to 6 months, speeding up development process
• Fully integrated approach to Quality by Design

Today, Recipharm announced the launch of ReciPredict, a cutting-edge platform for Quality by Design (QbD), designed to transform the landscape of drug product development, tech transfer and manufacturing. With its innovative combination and systematic application of material sciences, statistical tools and modelling and simulation, ReciPredict promises to deliver unparalleled efficiency and reliability to the pharmaceutical industry, by streamlining the product development cycle, from initial formulation through to manufacturing.

Dr. Uwe Hanenberg, PhD, Head of Product Implementation, said: "ReciPredict accelerates the journey of new drugs to the clinical stage by 3-6 months, substantially expediting the drug development process. It also offers significant cost savings by reducing API consumption by 30% to 70%. Another crucial advantage is that applying ReciPredict de-risks tech transfers by identifying the right parameters for best process robustness, consequently achieving consistent and high-quality results. This is a win-win for our customers and for patients, as it helps bring new drugs to market faster."

ReciPredict combines expertise in data science and statistics with powerful modelling and statistical tools. By leveraging advanced statistical models, ReciPredict connects critical process parameters, material attributes and drug product quality attributes. This comprehensive understanding enables Quality by Design with precise prediction of quality attributes based on material properties and process parameters.

Uwe Hanenberg continues: "ReciPredict offers an unparalleled understanding of materials and processes, enabling faster and more efficient drug development. As such, it provides great efficiencies by solving complex problems in product development, tech transfers, and routine manufacturing. Our key capabilities include an expert data science and statistics team, advanced modelling tools, comprehensive statistical tools, powder characterisation (FT4, Accupyc, BET, and more), and a Style One Evo compression and compaction simulator. These features collectively ensure that ReciPredict stands out as a robust and reliable platform in the pharmaceutical industry."

ReciPredict can be utilised across various stages and aspects of drug development and manufacturing, including: product development, trial design and DoE, data analysis, In Silico formulations, tech transfers and process & formulation optimisation. ReciPredict is versatile and can be applied to all sites, products and technologies, making it an invaluable tool for any pharmaceutical company looking to enhance their drug development and manufacturing processes.

For more information about ReciPredict or to schedule a discussion how ReciPredict can help with your project, please contact: Uwe Hanenberg ([email protected])

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,200 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its biologics segment, ReciBioPharm, works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the US and is headquartered in Stockholm, Sweden.

For more information on Recipharm, please visit www.recipharm.comand www.recibiopharm.com

Media contact:
Guenaelle Holloway, Head of communications
[email protected]
+44 7730 303 708

Introducing ReciPredict

Recipharm AB
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com